BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32227211)

  • 1. Late infectious complications in hematopoietic cell transplantation survivors: a population-based study.
    Foord AM; Cushing-Haugen KL; Boeckh MJ; Carpenter PA; Flowers MED; Lee SJ; Leisenring WM; Mueller BA; Hill JA; Chow EJ
    Blood Adv; 2020 Apr; 4(7):1232-1241. PubMed ID: 32227211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors.
    Chow EJ; Cushing-Haugen KL; Cheng GS; Boeckh M; Khera N; Lee SJ; Leisenring WM; Martin PJ; Mueller BA; Schwartz SM; Baker KS
    J Clin Oncol; 2017 Jan; 35(3):306-313. PubMed ID: 27870568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late Kidney Morbidity and Mortality in Hematopoietic Cell Transplant Survivors.
    Wu NL; Hingorani S; Cushing-Haugen KL; Lee SJ; Chow EJ
    Transplant Cell Ther; 2021 May; 27(5):434.e1-434.e6. PubMed ID: 33775588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late-occurring infections in a contemporary cohort of hematopoietic cell transplantation survivors.
    Sy A; Chanson D; Berano Teh J; Wong FL; Nakamura R; Dadwal S; Armenian SH
    Cancer Med; 2021 May; 10(9):2956-2966. PubMed ID: 33835722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.
    Goldman JM; Majhail NS; Klein JP; Wang Z; Sobocinski KA; Arora M; Horowitz MM; Rizzo JD
    J Clin Oncol; 2010 Apr; 28(11):1888-95. PubMed ID: 20212247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients.
    Solh MM; Bashey A; Solomon SR; Morris LE; Zhang X; Brown S; Holland HK
    Bone Marrow Transplant; 2018 May; 53(5):576-583. PubMed ID: 29335633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation.
    Atsuta Y; Hirakawa A; Nakasone H; Kurosawa S; Oshima K; Sakai R; Ohashi K; Takahashi S; Mori T; Ozawa Y; Fukuda T; Kanamori H; Morishima Y; Kato K; Yabe H; Sakamaki H; Taniguchi S; Yamashita T;
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1702-1709. PubMed ID: 27246369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age.
    Vrooman LM; Millard HR; Brazauskas R; Majhail NS; Battiwalla M; Flowers ME; Savani BN; Akpek G; Aljurf M; Bajwa R; Baker KS; Beitinjaneh A; Bitan M; Buchbinder D; Chow E; Dandoy C; Dietz AC; Diller L; Gale RP; Hashmi SK; Hayashi RJ; Hematti P; Kamble RT; Kasow KA; Kletzel M; Lazarus HM; Malone AK; Marks DI; O'Brien TA; Olsson RF; Ringden O; Seo S; Steinberg A; Yu LC; Warwick A; Shaw B; Duncan C
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1327-1334. PubMed ID: 28461213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34
    Scordo M; Shah GL; Kosuri S; Herrera DA; Cho C; Devlin SM; Maloy MA; Nieves J; Borrill T; Avecilla ST; Meagher RC; Carlow DC; O'Reilly RJ; Papadopoulos EB; Jakubowski AA; Koehne G; Gyurkocza B; Castro-Malaspina H; Tamari R; Perales MA; Giralt SA; Shaffer BC
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):133-141. PubMed ID: 28870777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease.
    Miller HK; Braun TM; Stillwell T; Harris AC; Choi S; Connelly J; Couriel D; Goldstein S; Kitko CL; Magenau J; Pawarode A; Reddy P; Riwes M; Yanik GA; Levine JE
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):522-528. PubMed ID: 28017733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study.
    Bhatia S; Francisco L; Carter A; Sun CL; Baker KS; Gurney JG; McGlave PB; Nademanee A; O'Donnell M; Ramsay NK; Robison LL; Snyder D; Stein A; Forman SJ; Weisdorf DJ
    Blood; 2007 Nov; 110(10):3784-92. PubMed ID: 17671231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
    Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
    Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation.
    Choi M; Sun CL; Kurian S; Carter A; Francisco L; Forman SJ; Bhatia S
    Cancer; 2008 Oct; 113(7):1580-7. PubMed ID: 18704986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States.
    Bhatt NS; Brazauskas R; Salit RB; Syrjala K; Bo-Subait S; Tecca H; Badawy SM; Baker KS; Beitinjaneh A; Bejanyan N; Byrne M; Dias A; Farhadfar N; Freytes CO; Ganguly S; Hashmi S; Hayashi RJ; Hong S; Inamoto Y; Jamani K; Kasow KA; Khera N; Krem MM; Lazarus HM; Lee CJ; Lee S; Majhail NS; Malone AK; Marks DI; Mau LW; Mayo SJ; Muffly LS; Nathan S; Nishihori T; Page KM; Preussler J; Rangarajan HG; Rotz SJ; Salooja N; Savani BN; Schears R; Schechter-Finkelstein T; Schiller G; Shah AJ; Sharma A; Wang T; Wirk B; Battiwalla M; Schoemans H; Hamilton B; Buchbinder D; Phelan R; Shaw B
    Transplant Cell Ther; 2021 Aug; 27(8):679.e1-679.e8. PubMed ID: 33895402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
    El-Jawahri A; Chen YB; Brazauskas R; He N; Lee SJ; Knight JM; Majhail N; Buchbinder D; Schears RM; Wirk BM; Wood WA; Ahmed I; Aljurf M; Szer J; Beattie SM; Battiwalla M; Dandoy C; Diaz MA; D'Souza A; Freytes CO; Gajewski J; Gergis U; Hashmi SK; Jakubowski A; Kamble RT; Kindwall-Keller T; Lazarus HM; Malone AK; Marks DI; Meehan K; Savani BN; Olsson RF; Rizzieri D; Steinberg A; Speckhart D; Szwajcer D; Schoemans H; Seo S; Ustun C; Atsuta Y; Dalal J; Sales-Bonfim C; Khera N; Hahn T; Saber W
    Cancer; 2017 May; 123(10):1828-1838. PubMed ID: 28102896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR).
    Gabriel M; Shaw BE; Brazauskas R; Chen M; Margolis DA; Sengelov H; Dahlberg A; Ahmed IA; Delgado D; Lazarus HM; Gibson B; Myers KC; Kamble RT; Abdel-Mageed A; Li CK; Flowers MED; Battiwalla M; Savani BN; Majhail N; Shaw PJ
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1320-1326. PubMed ID: 28411175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.